FrancophonIA/ELRC3.0 huggingface dataset:
English: During these trials, the most common circulating rotavirus genotype was G1P[8], while rotavirus genotypes G2P[4], G3P[8], G4P[8], and G9P[8] were identified less often.
Croatian: Tijekom tih ispitivanja, najčešći genotip rotavirusa u cirkulaciji je bio G1P[8], dok su genotipovi rotavirusa G2P[4], G3P[8], G4P[8] i G9P[8] bili rjeđi.
English: α
Croatian: A.
English: What RotaTeq is and what it is used for What you need to know before your child receives RotaTeq How to use RotaTeq
Croatian: Što je RotaTeq i za što se koristi Što morate znati prije nego
English: Clear the fluid from the dispensing tip by holding tube vertically and tapping the twist-off cap.
Croatian: Uklonite tekućinu s vrška držeći tubu okomito i lagano lupkajući prstom po zatvaraču na navoj.
English: RotaTeq does not protect against diarrhoea and vomiting due to causes other than rotavirus.
Croatian: RotaTeq ne štiti od proljeva i povraćanja uzrokovanih drugim uzročnicima osim rotavirusa.
English: No increased risk of Kawasaki disease was observed among infants receiving RotaTeq in a large postmarketing observational safety surveillance study (see section 5.1).
Croatian: U velikom opservacijskom ispitivanju praćenja sigurnosti nakon stavljanja u promet nije primijećen povećan rizik od Kawasakijeve bolesti u dojenčadi koja su primila RotaTeq (vidjeti dio 5.1).
English: It remains unclear whether rotavirus vaccines affect the overall incidence of intussusception based on longer periods of follow up (see section 4.4).
Croatian: I dalje nije jasno utječu li cjepiva protiv rotavirusa na ukupnu incidenciju intususcepcije na temelju duljeg razdoblja praćenja (vidjeti dio d. Druge posebne populacije Apneja u izrazito prerano rođene dojenčadi (rođene ≤28. tjedana gestacije) (vidjeti dio 4.4).
English: RotaTeq contains sucrose.
Croatian: RotaTeq sadrži saharozu.
English: Peak excretion occurred within 7 days of dosing.
Croatian: Vršno izlučivanje cjepiva je unutar 7 dana od doziranja.
English: The efficacy of RotaTeq was comparable between this subset of infants and infants born at term.
Croatian: Djelotvornost cjepiva RotaTeq kod ove podskupine dojenčadi bila je slična djelotvornosti kod dojenčadi rođene u terminu.
English: Marketing Authorisation Holder: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, France.
Croatian: Nositelj odobrenja za stavljanje lijeka u promet: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, Francuska.
English: After your child has received RotaTeq, contact a doctor/health care professional right away if your child experiences severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever (see also section 4 “Possible side effects”).
Croatian: Ako Vaše dijete osjeti jaku bol u trbuhu, uporno povraća, ima krv u stolici, nadut trbuh i/ili visoku vrućicu nakon što je primilo RotaTeq, odmah se javite liječniku/zdravstvenom radniku (pogledajte i dio 4. "Moguće nuspojave").
English: In REST, RotaTeq was administered to approximately 1,000 infants who were born at a gestational age of 25 to 36 weeks.
Croatian: U ispitivanju REST, RotaTeq je primilo približno 1000 dojenčadi rođenih od 25. do 36. tjedna gestacijske dobi.
English: Hospitalization and Emergency Department (ED) visits due to RVGE
Croatian: Hospitalizacija i dolazak na odjel hitne medicine zbog RVGE
English: - your child has any disease which reduces his/her resistance to infection.
Croatian: - ako je Vaše dijete rođeno s malformacijom probavnog sustava zbog koje bi moglo biti sklono intususcepciji. - ako Vaše dijete ima bilo kakvu bolest koja smanjuje otpornost na infekciju. - ako Vaše dijete ima tešku infekciju s visokom temperaturom.
English: In a subset of infants from 3 placebo-controlled clinical trials (n=6,130 recipients of RotaTeq and 5,560 placebo recipients), RotaTeq was evaluated for all adverse events within 42 days of vaccination with or without concomitant use of other paediatric vaccines.
Croatian: U 3 placebom kontrolirana klinička ispitivanja (n=6130 primatelja RotaTeq cjepiva te 5560 primatelja placeba), u podskupini dojenčadi praćeni su svi štetni događaji na RotaTeq, primijenjen samostalno ili istodobno s drugim cjepivima za dječju dob, unutar 42 dana od cijepljenja.
English: Adverse reactions following administration of RotaTeq in clinical trials and adverse events reported post-marketing (in italics)
Croatian: Nuspojave nakon primjene cjepiva RotaTeq u kliničkim ispitivanjima i nuspojave prijavljene nakon stavljanja u promet (u kurzivu) Klasifikacija organskih sustava Učestalost
English: There have been reports of administration of higher than recommended doses of RotaTeq.
Croatian: Prijavljeni su slučajevi primjene cjepiva RotaTeq u dozi većoj od preporučene.
English: Method of administration Rotateq is for oral administration only.
Croatian: Način primjene RotaTeq se primjenjuje samo peroralno.
English: - If your child gets any side effects, talk to your doctor or pharmacist.
Croatian: - Ako Vaše dijete razvije bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
English: Merck Sharp & Dohme Corp.
Croatian: Naziv tvrtke: Merck Sharp & Dohme Corp.
English: Transmission of vaccine virus strains to non-vaccinated contacts has been observed post-marketing.
Croatian: U razdoblju nakon stavljanja cjepiva u promet primijećen je prijenos sojeva virusa iz cjepiva na osobe u kontaktu koje nisu bile cijepljenje.
English: What you need to know before your child receives RotaTeq
Croatian: Vaše dijete primi RotaTeq
English: The administration of RotaTeq should be postponed in subjects suffering from acute diarrhoea or vomiting.
Croatian: Primjena RotaTeq cjepiva se mora odgoditi u dojenčadi koja imaju akutni proljev ili povraćaju.
English: Serious adverse reactions were assessed in all participants (36,150 recipients of RotaTeq and 35,536 placebo recipients) of 3 clinical trials for up to 42 days after each dose.
Croatian: Svi ispitanici (36 150 primatelja cjepiva RotaTeq te 35 536 primatelja placeba) iz 3 klinička ispitivanja praćeni su zbog ozbiljnih nuspojava tijekom 42 dana nakon primitka pojedine doze cjepiva.
English: Efficacy against genotypes G2P[4], G3P[8], G4P[8] and G9P[8] rotavirus was based on fewer cases than for G1.
Croatian: Zaštitna djelotvornost protiv rotavirusa genotipa G2P[4], G3P[8], G4P[8] i G9P[8] temeljena je na manje slučajeva nego za rotavirus genotipa G1. Procjena zaštitne djelotvornosti cjepiva protiv genotipa G2P[4] najvjerojatnije proizlazi iz G2 genotipa rotavirusa u cjepivu.
English: Intussusception
Croatian: Intususcepcija
English: The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
Croatian: Kod izrazito rano rođene dojenčadi (rođene ≤28. tjedna gestacije), a pogotovo kod onih s anamnezom respiratorne nezrelosti treba uzeti u obzir potencijalni rizik od apneje i potrebu za nadzorom respiracije tijekom 48-72 sata nakon primjene prve doze cjepiva.
English: Co-administration of RotaTeq with DTaP-IPV-HBV-Hib vaccine (Infanrix hexa) at approximately 2, 3, and 4 months of age demonstrated that the immune responses and the safety profiles of the co-administered vaccines were unaffected compared to separate administrations.
Croatian: Pokazalo se da, u usporedbi sa zasebnom primjenom, istodobna primjena cjepiva RotaTeq s cjepivima DTaP-IPV-HBV-Hib (Infanrix hexa) u dojenčadi u dobi od približno 2, 3 i 4 mjeseca ne utječe na imunološki odgovor i profile sigurnosti tih istodobno primijenjenih cjepiva.
English: From birth to 6 weeks RotaTeq is not indicated in this subset of paediatric population.
Croatian: RotaTeq nije indiciran u ovoj podskupini pedijatrijske populacije.
English: How to use RotaTeq.
Croatian: Kako primjenjivati RotaTeq.
English: RotaTeq may be given to infants who were born early provided that the pregnancy had lasted at least 25 weeks.
Croatian: RotaTeq se može dati prijevremeno rođenoj dojenčadi ako su rođena nakon navršenog 25. tjedna trudnoće.
English: Uncommon Haematochezia †, Abdominal pain upper
Croatian: Manje često hematohezija †, bolovi u gornjem dijelu abdomena Vrlo rijetko intususcepcija α*
English: Tel.: +48.22.549.51.00 msdpolska@merck.com
Croatian: MSD Polska Sp. z o.o. Tel.: +48.22.549.51.00 msdpolska@merck.com
English: If your child gets any side effects, talk to your doctor or pharmacist.
Croatian: Ako u Vašeg djeteta primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
English: As with any vaccine, vaccination with RotaTeq may not result in complete protection in all recipients.
Croatian: Kao i ostala cjepiva, RotaTeq neće nužno zaštititi sve koji su primili cjepivo.
English: The active substances in RotaTeq are 5 human-bovine reassortant rotavirus strains: G1 2.2 x 10
Croatian: Djelatne tvari u cjepivu RotaTeq su 5 sojeva reasortanata humano-bovinih rotavirusa:
English: How to use RotaTeq
Croatian: Kako primjenjivati RotaTeq
English: 2,102 unvaccinated Aged <2 years
Croatian: 1895 cijepljenih s 3 doze 2102 necijepljenih U dobi od <2 godine
English: Any severity (G1-G4)
Croatian: Svi oblici (G1-G4)
English: Not known
Croatian: Što morate znati prije nego
English: Gastroenteritis with vaccine viral shedding in infants with Severe Combined Immunodeficiency Disease (SCID) has been reported post-marketing.
Croatian: Nakon stavljanja u promet, u dojenčadi s teškom kombiniranom imunodeficijencijom zabilježen je gastroenteritis s izlučivanjem virusa iz cjepiva.
English: Previous history of intussusception.
Croatian: Intususcepcija u anamnezi.
English: Sodium citrate
Croatian: Oralna otopina
English: How to store RotaTeq
Croatian: Kako čuvati RotaTeq
English: - has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system.
Croatian: Vaše dijete primi RotaTeq ako je: - u posljednjih 6 tjedana transfuzijom primilo krv ili imunoglobuline. - u bliskom doticaju s ukućanom kojemu je slab imunološki sustav, poput osoba koje boluju od raka ili osoba koje primaju lijekove koji mogu oslabiti imunološki sustav. - ima bilo kakav poremećaj probavnog sustava. - ne raste ili ne dobiva na težini koliko bi trebalo.
English: rotavirus type* G1
Croatian: rotavirus serotipa* G1
English: Ask your doctor/health care professional if you want more information about side effects for RotaTeq.
Croatian: Želite li više saznati o nuspojavama vezanim uz RotaTeq obratite se svom liječniku/zdravstvenom radniku.
English: Cases of gastroenteritis associated with vaccine virus have been reported post marketing in infants with severe combined immunodeficiency (SCID, see section 4.3).
Croatian: U razdoblju nakon stavljanja cjepiva u promet u dojenčadi s teškom kombiniranom imunodeficijencijom (vidjeti dio 4.3) zabilježeni su slučajevi gastroenteritisa povezani s virusom cjepiva.
English: Slovenská republika Merck Sharp & Dohme, s. r. o Tel: +421 2 58282010 dpoc_czechslovak@merck.com
Croatian: Česká republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 dpoc_czechslovak@merck.com
English: rotavirus type* G4
Croatian: rotavirus serotipa* G4
English: Magyarország MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300 hungary_msd@merck.com
Croatian: Tel.: + 36.1.888.5300 hungary_msd@merck.com
English: rotavirus type* G3
Croatian: rotavirus serotipa* G3
English: rotavirus type* G2
Croatian: rotavirus serotipa* G2
English: To administer the vaccine:
Croatian: Primjena cjepiva:
English: not less than 2.3 x 10 6 IU
Croatian: ne manje od 2,3 x 10 6 IU
English: Reporting of side effects
Croatian: Podaci iz ispitivanja učinkovitosti
English: not less than 2.8 x 10 6 IU
Croatian: ne manje od 2,8 x 10 6 IU
English: not less than 2.0 x 10 6 IU
Croatian: ne manje od 2,0 x 10 6 IU
English: not less than 2.2 x 10 6 IU
Croatian: ne manje od 2,2 x 10 6 IU
English: Merck Sharp and Dohme BV
Croatian: Naziv tvrtke: Merck Sharp & Dohme BV Adresa:
English: Tel: +385 1 66 11 333 croatia_info@merck.com
Croatian: Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 333 croatia_info@merck.com
English: Sodium dihydrogen phosphate monohydrate Sodium hydroxide
Croatian: 6.1 Popis pomoćnih tvari saharoza natrijev citrat natrijev dihidrogenfosfat hidrat natrijev hidroksid polisorbat 80 podloga za kultiviranje (sadrži anorganske soli, aminokiseline i vitamine) voda, pročišćena
English: Case-control study (US)
Croatian: Ispitivanje parova (SAD)
English: RotaTeq Oral solution Oral use
Croatian: RotaTeq oralna otopina kroz usta
English: Administration of RotaTeq may be considered with caution in such infants when, in the opinion of the physician, withholding the vaccine entails a greater risk.
Croatian: Ako liječnik smatra da bi takvo dojenče bilo pod većim rizikom ako ne primi cjepivo, treba razmotriti primjenu RotaTeq cjepiva uz mjere opreza.
English: Sucrose
Croatian: saharoza
English: : + 359 2 819 3737 info-msdbg@merck.com
Croatian: Мерк Шарп и Доум България ЕООД, тел.: + 359 2 819 3737 info-msdbg@merck.com
English: RotaTeq IS FOR ORAL USE ONLY.
Croatian: RotaTeq SE PRIMJENJUJE ISKLJUČIVO KROZ USTA.
English: Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00 msdromania@merck.com
Croatian: Tel: + 4021 529 29 00 msdromania@merck.com
English: Saxenda is injected once per day, preferably at the same time every day.
Croatian: Saxenda se injektira jednom na dan, po mogućnosti u isto vrijeme svaki dan.
English: The doctor should re-assess the need of continuing treatment once a year.
Croatian: Liječnik treba ocijeniti potrebu za nastavkom terapije jednom na godinu.
English: Weight loss was more pronounced in women than in men.
Croatian: Gubitak tjelesne mase je bio naglašeniji u žena nego u muškaraca.
English: The starting dose is 0.6 mg per day.
Croatian: Početna doza iznosi 0,6 mg na dan.
English: This summary was last updated in 03-2015.
Croatian: Sažetak je posljednji put ažuriran u 03.2015.
English: Saxenda liraglutide
Croatian: Saxenda liraglutid
English: The dose is then increased each week by 0.6 mg to a maximum of 3.0 mg per day.
Croatian: Doza se zatim povećava svaki tjedan za 0,6 mg do maksimalno 3,0 mg na dan.
English: The medicine can only be obtained with a prescription.
Croatian: Lijek izdaje samo na liječnički recept.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Saxenda on 23 March 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Saxenda na snazi u Europskoj uniji od 23. ožujka 2015.
English: It is not intended to provide practical advice on how to use Saxenda.
Croatian: Svrha sažetka nije davati praktične savjete o načinu korištenja lijeka Saxenda.
English: Further information on the long-term safety of liraglutide (particularly its effects on the heart and blood vessels) is expected from an ongoing study with Victoza.
Croatian: Više informacija o dugoročnoj sigurnoj primjeni liraglutida (posebice njegovom djelovanju na srce i krvne žile) očekuje se iz ispitivanja koje se trenutno provodi s lijekom Victoza.
English: The exact way that Saxenda works in weight loss is not fully understood, but it appears to act on the parts of the brain that regulate appetite, by attaching to GLP-1 receptors in brain cells and thereby increasing feelings of fullness and lowering feelings of hunger.
Croatian: Točan način djelovanja Saxenda u gubitku tjelesne težine nije u potpunosti poznat, no čini se da djeluje na dijelove mozga koji reguliraju apetit tako što se vezuje receptore GLP-1 u moždanim stanicama, te na taj način povećava osjećaj sitosti i smanjuje osjećaj gladi.
English: This is a summary of the European public assessment report (EPAR) for Saxenda.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Saxenda.
English: To limit these effects, when starting treatment the dose of Saxenda is slowly increased over 4 weeks.
Croatian: Kako bi se ove nuspojave ograničile, prilikom početka terapije doza lijeka Saxenda se polako povećava tijekom 4 tjedna.
English: The active substance in Saxenda, liraglutide, is a ‘glucagon-like peptide-1 (GLP-1) receptor agonist' that is already authorised in the EU as Victoza at lower doses (up to 1.8 mg per day) for the treatment of type 2 diabetes.
Croatian: Djelatna tvar lijeka Saxenda, liraglutid, je "agonist receptora glukagonu sličnog peptida-1 (GLP-1)" koji je već odobren u EU pod nazivom Victoza u manjim dozama (do 1,8 mg na dan) za terapiju dijabetesa tipa 2.
English: The CHMP considered that Saxenda has a modest (particularly in men) but still clinically relevant effect on weight loss.
Croatian: CHMP je zaključio da lijek Saxenda ima umjereno (posebice u muškaraca), no još uvijek klinički značajno djelovanje na gubitak tjelesne mase.
English: What is Saxenda and what is it used for?
Croatian: Što je Saxenda i za što se koristi?
English: • who are obese (have a body-mass index - BMI - of 30 or more);
Croatian: • koji su pretili (imaju indeks tjelesne mase - ITM - jednak ili veći od 30)
English: Why is Saxenda approved?
Croatian: Zašto je Saxenda odobren?
English: • who are overweight (have a BMI between 27 and 30) and have weight-related complications such as diabetes, abnormally high levels of fat in the blood, high blood pressure or obstructive sleep apnoea (frequent interruption of breathing during sleep).
Croatian: • s prekomjernom tjelesnom težinom (imaju ITM između 27 i 30) uz prisutnost najmanje jednog komorbiditeta povezanog s tjelesnom težinom kao što je dijabetes, abnormalno visoke razine masti u krvi, visoki krvni tlak ili opstruktivna apneja u snu (često prekidanje disanja tijekom spavanja).
English: What measures are being taken to ensure the safe and effective use of Saxenda?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Saxenda?
English: When the figures for the main studies were re-analysed using a more conservative method that assumed that patients who did not complete the study (around 30%) would not have seen any improvement, similar but smaller weight reductions with Saxenda were noted.
Croatian: Nakon što su brojke glavnog ispitivanja ponovno analizirane primjenom konzervativnije metode koja je pretpostavila da bolesnici koji nisu završili ispitivanje (otprilike 30%) ne bi uočili ikakvo poboljšanje, uočen je sličan no smanjen gubitak tjelesne mase s lijekom Saxenda.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Saxenda's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Saxenda nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Looking at the results of the 5 studies together, Saxenda at a daily dose of 3 mg led to a 7.5% reduction in body weight, compared with a 2.3% reduction in patients taking placebo.
Croatian: Promatrajući zajedno rezultate 5 ispitivanja, Saxenda u dnevnoj dozi od 3 mg rezultirala je smanjenjem tjelesne težine od 7,5% u usporedbi sa smanjenjem od 2,3% u bolesnika koji su uzimali placebo.
English: BMI is a measurement that indicates body weight relative to height.
Croatian: ITM jest mjera koja prikazuje omjer tjelesne težine i visine.
English: Other information about Saxenda
Croatian: Ostale informacije o lijeku Saxenda
English: Treatment with Saxenda should be stopped if patients have not lost at least 5% of their initial body weight after 12 weeks of treatment with 3 mg of Saxenda per day.
Croatian: Terapiju lijekom Saxenda treba prekinuti ako bolesnici nisu izgubili najmanje 5% svoje prvotne tjelesne mase nakon 12 tjedana terapije s 3 mg lijeka Saxenda na dan.
English: Patients in the studies were given the medicine as part of a weight loss programme involving counselling and advice on diet and exercise.
Croatian: Bolesnicima u ispitivanjima dan je lijek kao dio programa za smanjenje težine koji je obuhvaćao savjetovanje i savjete o prehrani i vježbanju.
English: Saxenda is available as a solution for injection in pre-filled pens.
Croatian: Saxenda je dostupan kao otopina za injekciju u napunjenim brizgalicama.
English: It is given as an injection under the skin in the thigh, upper arm or abdomen (belly).
Croatian: Daje se u obliku potkožne injekcije u bedro, nadlakticu ili abdomen (trbuh).
English: A risk management plan has been developed to ensure that Saxenda is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Saxenda.
English: The most common side effects with Saxenda (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, diarrhoea and constipation.
Croatian: Najčešće nuspojave lijeka Saxenda (mogu se javiti u više od 1 na 10 osoba) su mučnina (osjećaj slabosti), povraćanje, proljev i zatvor.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Saxenda, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Saxenda nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Saxenda is a medicine used along with diet and exercise to help manage weight in adults:
Croatian: Saxenda je lijek koji se koristi kao dodatak dijeti i povećanoj fizičkoj aktivnosti za kontrolu tjelesne težine u odraslih bolesnika:
English: What are the risks associated with Saxenda?
Croatian: Koji su rizici povezani s lijekom Saxenda?
English: Patients treated with Saxenda had a continuous decrease in body weight during the first 40 weeks of treatment, after which the weight loss achieved was maintained.
Croatian: U bolesnika liječenih lijekom Saxenda zabilježeno je kontinuirano je smanjenje u tjelesnoj masi tijekom prvih 40 tjedana terapije nakon kojih je postignuto smanjenje tjelesne mase zadržano.
English: Saxenda has been shown to be effective at reducing body weight in 5 main studies involving over 5,800 obese or overweight patients and lasting up to 56 weeks, in which Saxenda was compared with placebo (a dummy treatment).
Croatian: U 5 glavnih ispitivanja utvrđeno je da je lijek Saxenda djelotvoran u snižavanju tjelesne mase koja su obuhvatila više od 5.800 pretilih bolesnika ili bolesnika s prekomjernom tjelesnom težinom, a koja su trajala do 56 tjedana i u kojima je lijek Saxenda bio uspoređen s placebom (prividnim liječenjem).
English: Regarding safety, the most common side effects with Saxenda relate to the stomach and gut such as nausea.
Croatian: Vezano uz sigurnu primjenu, najčešće nuspojave povezane s lijekom Saxenda povezane su sa želucem i crijevima, poput mučnine.
English: Saxenda contains the active substance liraglutide.
Croatian: Sadrži djelatnu tvar liraglutid.
English: For practical information about using Saxenda, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Saxenda pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: The full EPAR and risk management plan summary for Saxenda can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Saxenda nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Saxenda pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: How does Saxenda work?
Croatian: Kako djeluje Saxenda?
English: What benefits of Saxenda have been shown in studies?
Croatian: Koje su koristi lijeka Saxenda utvrđene u ispitivanjima?
English: How is Saxenda used?
Croatian: Kako se Saxenda koristi?